文献速递神经免疫

多发性硬化中磁共振成像稳定的急性临床事件被识别为复发

Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项多中心观察性队列研究基于法国多发性硬化登记数据,纳入608例复发缓解型多发性硬化患者的637次临床事件,发现26.1%被识别为复发的事件在脑和脊髓磁共振成像上无新发病灶,称为磁共振稳定的急性临床事件(ACES)。ACES与更长的病程、疲劳及高效疾病修正治疗相关,且与随后更高的复发率、确认的残疾累积和继发进展风险相关。

要点

  • 在637次临床复发事件中,166次(26.1%)为磁共振稳定的急性临床事件(ACES)。
  • ACES在高效疾病修正治疗、病程较长(OR 1.04)或疲劳(OR 2.14)的患者中更常见。
  • ACES患者继发进展风险显著更高(HR 2.58),且ACES发生率在不同疾病修正治疗间保持稳定。

核心结论

  • 本研究提出多发性硬化中ACES的概念,ACES占被识别为复发的临床事件的四分之一。

研究设计与样本

  • 多中心观察性队列研究,数据于2023年6月8日从法国多发性硬化登记处提取,纳入2015年1月至2023年6月间复发缓解型多发性硬化患者的临床事件,要求事件前脑磁共振成像在12个月内、脊髓磁共振成像在24个月内完成,事件后50天内完成钆增强磁共振成像。
  • 共纳入608例患者的637次临床事件,其中女性493例(77.4%),平均(标准差)年龄35.8(10.7)岁。

主要发现

  • 在31 885次临床事件中,637次被纳入分析,ACES占166次(26.1%)。
  • ACES与更长的病程相关(OR 1.04;95% CI 1.01-1.07),与疲劳相关(OR 2.14;95% CI 1.15-3.96),在接收高效疾病修正治疗的患者中更常见。
  • ACES与EDSS评分显著增加相关,但增加幅度低于复发伴活动性磁共振成像(RAM)。
  • ACES患者事件前复发率更高(RR 1.21;95% CI 1.01-1.46),确认的残疾累积风险更高(HR 1.54;95% CI 1.13-2.11),复发相关恶化风险更高(HR 1.72;95% CI 1.20-2.45)。
  • ACES患者继发进展型多发性硬化转变风险显著更高(HR 2.58;95% CI 1.02-6.51);RAM发生率随疾病修正治疗预期疗效下降,而ACES发生率在不同治疗间保持稳定。

关键数值与推荐

  • ACES定义为被识别为复发但脑或脊髓磁共振成像上无新发T2病灶或钆增强T1病灶的急性临床事件;RAM定义为出现新发T2病灶或钆增强T1病灶的复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Understanding the association between clinically defined relapses and radiological activity in multiple sclerosis (MS) is essential for patient treatment and therapeutic development. OBJECTIVE: To investigate clinical events identified as relapses but not associated with new T2 lesions or gadolinium-enhanced T1 lesions on brain and spinal cord magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This multicenter observational cohort study was conducted between January 2015 and June 2023. Data were extracted on June 8, 2023, from the French MS registry. All clinical events reported as relapses in patients with relapsing-remitting MS were included if brain and spinal cord MRI was performed within 12 and 24 months before the event, respectively, and 50 days thereafter with gadolinium injection. EXPOSURES: Events were classified as relapses with active MRI (RAM) if a new T2 lesion or gadolinium-enhanced T1 lesion appeared on brain or spinal cord MRI or as acute clinical events with stable MRI (ACES) otherwise. MAIN OUTCOMES AND MEASURES: Factors associated with ACES were investigated; patients with ACES and RAM were compared regarding Expanded Disability Status Scale (EDSS) course, relapse rate, confirmed disability accrual (CDA), relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and transition to secondary progressive (SP) MS, and ACES and RAM rates under each disease-modifying therapy (DMT) were estimated. RESULTS: Among 31 885 clinical events, 637 in 608 patients (493 [77.4%] female; mean [SD] age, 35.8 [10.7] years) were included. ACES accounted for 166 (26.1%) events and were more likely in patients receiving highly effective DMTs, those with longer disease duration (odds ratio [OR], 1.04; 95% CI, 1.01-1.07), or those presenting with fatigue (OR, 2.14; 95% CI, 1.15-3.96). ACES were associated with significant EDSS score increases, lower than those found for RAM. Before the index event, patients with ACES experienced significantly higher rates of relapse (relative rate [RR], 1.21; 95% CI, 1.01-1.46), CDA (hazard ratio [HR], 1.54; 95% CI, 1.13-2.11), and RAW (HR, 1.72; 95% CI, 1.20-2.45). Patients with ACES were at significantly greater risk of SP transition (HR, 2.58; 95% CI, 1.02-6.51). Although RAM rate decreased with DMTs according to their expected efficacy, ACES rate was stable across DMTs. CONCLUSIONS AND RELEVANCE: The findings in this study introduce the concept of ACES in MS, which accounted for one-fourth of clinical events identified as relapses.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Gavoille A, Rollot F, Casey R, et al. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis. JAMA Neurol. 2024. PMID: 38949816. doi:10.1001/jamaneurol.2024.1961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。